International Society Of Neuropathology--Haarlem consensus guidelines for nervous system tumor classification and grading

DOI: 10.1111/bpa.12171
Brain Pathology, 2014, 24, 429-35.

#	Paper	IF	Citations
465	Protein residues that control the reaction trajectory in S-adenosylmethionine radical enzymes: mutagenesis of asparagine 153 and aspartate 155 in Escherichia coli biotin synthase. **2009**, 48, 2448-58		20
464	Molecular characteristics of pediatric high-grade gliomas. **2014**, 3, 433-43		24
463	Molecular insights into pediatric brain tumors have the potential to transform therapy. **2014**, 20, 5630-40		93
462	The evolving role of molecular markers in the diagnosis and management of diffuse glioma. **2014**, 20, 5601-11		44
461	Embryonal tumor with multilayered rosettes (ETMR): signed, sealed, delivered **2014**, 128, 305-8		11
460	Glioma. **2015**, 1, 15017		368
459	Impending Impact of Molecular Pathology on Classifying Adult Diffuse Gliomas. **2015**, 22, 200-5		8
458	PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients. **2015**, 3, 88		27
457	CDKN2A loss is associated with shortened overall survival in lower-grade (World Health Organization Grades II-III) astrocytomas. **2015**, 74, 442-52		91
456	Overexpression and Nucleolar Localization of Tubulin Small Complex Proteins GCP2 and GCP3 in Glioblastoma. **2015**, 74, 723-42		18
455	Pediatric gliomas as neurodevelopmental disorders. **2016**, 64, 879-95		32
454	ETV/Pea3 family transcription factor-encoding genes are overexpressed in CIC-mutant oligodendrogliomas. **2015**, 54, 725-33		33
453	Towards an integrated morphological and molecular WHO diagnosis of central nervous system tumors: a paradigm shift. **2015**, 28, 628-32		4
452	Radiological and pathological features associated with IDH1-R132H mutation status and early mortality in newly diagnosed anaplastic astrocytic tumours. **2015**, 10, e0123890		20
451	Combination genetic signature stratifies lower-grade gliomas better than histological grade. **2015**, 6, 20885-901		35
450	Targeting the Hedgehog Pathway in Pediatric Medulloblastoma. *Cancers*, **2015**, 7, 2110-23	6.6	33
449	The evolving molecular genetics of low-grade glioma. **2015**, 22, 94-101		59

448	Emerging microtubule targets in glioma therapy. **2015**, 22, 49-72		28
447	Glioma Groups Based on 1p/19q, IDH, and TERT Promoter Mutations in Tumors. **2015**, 372, 2499-508		1181
446	Brain Tumor Imaging. **2015**, 1-9		1
445	Glioblastoma: molecular pathways, stem cells and therapeutic targets. *Cancers*, **2015**, 7, 538-55	6.6	83
444	Oligodendroglioma: pathology, molecular mechanisms and markers. **2015**, 129, 809-27		128
443	IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO. **2015**, 129, 867-73		200
442	Diffusely infiltrating astrocytomas: pathology, molecular mechanisms and markers. **2015**, 129, 789-808		39
441	FISHing Tips: What Every Clinician Should Know About 1p19q Analysis in Gliomas Using Fluorescence in situ Hybridisation. **2015**, 27, 445-53		20
440	[Classification of gliomas. Current progress and perspectives]. **2015**, 86, 672, 674-6, 678-80, passim		3
439	Biomarker-driven diagnosis of diffuse gliomas. **2015**, 45, 87-96		57
438	Diagnostic, prognostic and predictive relevance of molecular markers in gliomas. **2015**, 41, 694-720		72
437	Mir-21-Sox2 Axis Delineates Glioblastoma Subtypes with Prognostic Impact. **2015**, 35, 15097-112		41
436	Mixed glioma with molecular features of composite oligodendroglioma and astrocytoma: a true "oligoastrocytoma"?. **2015**, 129, 151-3		68
435	New strategies in glioblastoma: exploiting the new biology. **2015**, 21, 1984-8		30
434	Medulloblastoma: toward biologically based management. **2015**, 22, 6-13		17
433	Liquid biopsies in patients with diffuse glioma. **2015**, 129, 849-65		62
432	Oligoastrocytomas: throwing the baby out with the bathwater?. **2015**, 129, 147-9		47
431	Farewell to oligoastrocytoma: response to letters. **2015**, 129, 155		7

430	Emerging Molecularly-Targeted Therapeutic Strategies in Brain Cancer. Introduction. **2015**, 22, 2-4		1
429	Adult IDH wild type astrocytomas biologically and clinically resolve into other tumor entities. **2015**, 130, 407-17		194
428	Multiple Molecular Data Sets and the Classification of Adult Diffuse Gliomas. **2015**, 372, 2555-7		28
427	Discrimination between two different grades of human glioma based on blood vessel infrared spectral imaging. **2015**, 407, 7295-305		10
426	Novel Surgical Approaches to High-Grade Gliomas. **2015**, 17, 369		6
425	60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models. **2015**, 226, T161-72		25
424	Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. **2015**, 372, 2481-98		1828
423	A wide spectrum of EGFR mutations in glioblastoma is detected by a single clinical oncology targeted next-generation sequencing panel. **2015**, 98, 568-73		11
422	[Molecular diagnostics in neuropathology]. **2015**, 36, 171-80		11
421	IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. **2015**, 129, 585-96		211
420	Anaplastic oligoastrocytoma: is molecular stratification based on 1p/19q status alone appropriate?. **2015**, 122, 217-8		3
419	Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011. **2015**, 123, 43-51		22
418	Primary melanocytic tumors of the central nervous system: a review with focus on molecular aspects. *Brain Pathology*, **2015**, 25, 209-26	6	64
417	Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups. **2015**, 129, 679-93		208
416	Evidence-Based Diagnostic Algorithm for Glioma: Analysis of the Results of Pathology Panel Review and Molecular Parameters of EORTC 26951 and 26882 Trials. **2015**, 33, 1943-50		13
415	Molecular pathways in gliomagenesis and their relevance to neuropathologic diagnosis. **2015**, 22, 50-8		62
414	Pilocytic astrocytoma: pathology, molecular mechanisms and markers. **2015**, 129, 775-88		229
413	Highlights from the Literature. **2015**, 17, 485-487		78

412	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. **2015**, 17, 1344-55		39
411	Molecular Markers in Low-Grade Glioma-Toward Tumor Reclassification. **2015**, 25, 155-63		41
410	Emerging circulating biomarkers in glioblastoma: promises and challenges. **2015**, 15, 1311-23		45
409	Allelic loss of 9p21.3 is a prognostic factor in 1p/19q codeleted anaplastic gliomas. **2015**, 85, 1325-31		25
408	The role of neuropathology in the management of patients with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. **2015**, 125, 531-49		29
407	: newly diagnosed glioblastoma. **2015**, 2, 106-121		8
406	Of Brains and Blood: Developmental Origins of Glioma Diversity?. **2015**, 28, 403-404		3
405	A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance. **2015**, 22, 417-30		96
404	Circulating biomarkers for gliomas. **2015**, 11, 556-66		116
403	Rapid Intraoperative Molecular Characterization of Glioma. **2015**, 1, 662-7		53
402	Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner. **2015**, 17, 564-73		37
401	ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an "integrated" diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma. **2015**, 129, 133-46		313
400	Prognostic Relevance of Histomolecular Classification of Diffuse Adult High-Grade Gliomas with Necrosis. *Brain Pathology*, **2015**, 25, 418-28	6	6
399	Detection of ATRX and IDH1-R132H immunohistochemistry in the progression of 211 paired gliomas. **2016**, 7, 16384-95		40
398	Canadian brain cancer survival rates by tumour type and region: 1992-2008. **2016**, 107, e37-e42		12
397	ATRX, IDH1-R132H and Ki-67 immunohistochemistry as a classification scheme for astrocytic tumors. **2016**, 3, 258-265		31
396	Treatment of Adult Lower-Grade Glioma in the Era of Genomic Medicine. **2016**, 35, 75-81		10
395	A Randomized Clinical Trial of Radiation With or Without Chemotherapy for Low-grade Gliomas. **2016**, 79, N17-8		1

394	Not all 1p/19q non-codeleted oligodendroglial tumors are astrocytic. **2016**, 7, 64615-64630		17
393	Cognitive Rehabilitation in Patients with Gliomas and Other Brain Tumors: State of the Art. **2016**, 2016, 3041824		30
392	Evolving Molecular Genetics of Glioblastoma. **2016**, 129, 464-71		32
391	Comprehensive Genomic Analysis of Infiltrative Gliomas Based on Molecular Profile. **2016**, 78, N15-6		
390	Impact of gross total resection in patients with WHO grade III glioma harboring the IDH 1/2 mutation without the 1p/19q co-deletion. **2016**, 129, 505-514		84
389	Long-term analysis of the NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with PCV or temozolomide. **2016**, 18, 1529-1537		80
388	Integrating Molecular Subclassification of Medulloblastomas into Routine Clinical Practice: A Simplified Approach. *Brain Pathology*, **2016**, 26, 334-43	6	31
387	A 14-Year-Old Boy with Left Temporal Mass. *Brain Pathology*, **2016**, 26, 293-4	6	
386	A Global View on the Availability of Methods and Information in the Neuropathological Diagnostics of CNS Tumors: Results of an International Survey Among Neuropathological Units. *Brain Pathology* , **2016**, 26, 551-4	6	8
385	Integrated analysis identified genes associated with a favorable prognosis in oligodendrogliomas. **2016**, 55, 169-76		3
384	Combined ATRX/IDH1 immunohistochemistry predicts genotype of oligoastrocytomas. **2016**, 68, 272-8		17
383	Utility of ATRX immunohistochemistry in diagnosis of adult diffuse gliomas. **2016**, 69, 260-7		37
382	Atypical teratoid rhabdoid tumor involving the nasal cavities and anterior skull base. **2016**, 36, 283-289		7
381	Biological Significance of Mutant Isocitrate Dehydrogenase 1 and 2 in Gliomagenesis. **2016**, 56, 170-9		11
380	IDH-mutant glioma specific association of rs55705857 located at 8q24.21 involves MYC deregulation. **2016**, 6, 27569		18
379	TERT Promoter Mutations but not the Alternative Lengthening of Telomeres Phenotype Are Present in a Subset of Ependymomas and Are Associated With Adult Onset and Progression to Ependymosarcoma. **2017**, 76, 61-66		6
378	Copy Number Profiling of Brazilian Astrocytomas. **2016**, 6, 1867-78		5
377	Case 38-2016. A 52-Year-Old Woman with Recurrent Oligodendroglioma. **2016**, 375, 2381-2389		3

376	REST represses miR-124 and miR-203 to regulate distinct oncogenic properties of glioblastoma stem cells. **2017**, 19, 514-523	12
375	Management of Medulloblastoma in the Pediatric Population. **2016**, 38, 1-7	
374	Medulloblastoma: Tumor Biology and Relevance to Treatment and Prognosis Paradigm. **2016**, 16, 43	36
373	Mitotic index, microvascular proliferation, and necrosis define 3 pathological subgroups of prognostic relevance among 1p/19q co-deleted anaplastic oligodendrogliomas. **2016**, 18, 888-90	12
372	Downregulation of HIF-1a sensitizes U251 glioma cells to the temozolomide (TMZ) treatment. **2016** , 343, 148-158	25
371	Diagnostic performance of texture analysis on MRI in grading cerebral gliomas. **2016**, 85, 824-9	108
370	Novel cellular and post-genomic technologies in the treatment of glioblastoma multiforme (Review). **2016**, 35, 639-48	7
369	CGCG clinical practice guidelines for the management of adult diffuse gliomas. **2016**, 375, 263-273	253
368	Molecular classification of gliomas. **2016**, 134, 97-120	65
367	The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. **2016**, 131, 803-20	8580
366	Recent Advances on the Molecular Pathology of Glial Neoplasms in Children and Adults. **2016**, 18, 620-634	37
365	PET imaging in glioma: is it time for mainstream practice?. **2016**, 18, 1193-4	2
364	Cancer stem cells and microglia in the processes of glioblastoma multiforme invasive growth. **2016**, 12, 1721-1728	9
363	Neuropathology and molecular diagnosis of brain tumors. Where are we in 2015? An international survey on diagnostic practices. **2016**, 100, 168	
362	Pediatric low-grade gliomas: implications of the biologic era. **2017**, 19, 750-761	47
361	Integrating molecular markers into the World Health Organization classification of CNS tumors: a survey of the neuro-oncology community. **2017**, 19, 336-344	15
360	Analysis of expression and prognostic significance of vimentin and the response to temozolomide in glioma patients. **2016**, 37, 15333-15339	28
359	Extracranial oral cavity metastasis from glioblastoma multiforme: A case report. **2016**, 5, 437-439	5

358	Conventional chemotherapy and perspectives for molecular-based oncological treatment in pediatric hemispheric low-grade gliomas. **2016**, 32, 1939-45		3
357	WHO's arrived in 2016! An updated weather forecast for integrated brain tumor diagnosis. *Brain Tumor Pathology*, **2016**, 33, 157-60	3.2	11
356	Sequencing Structural Variants in Cancer for Precision Therapeutics. **2016**, 32, 530-542		55
355	Prognostic impact of the 2016 WHO classification of diffuse gliomas in the French POLA cohort. **2016**, 132, 625-34		72
354	Prognostic Stratification of GBMs Using Combinatorial Assessment of IDH1 Mutation, MGMT Promoter Methylation, and TERT Mutation Status: Experience from a Tertiary Care Center in India. **2016**, 9, 371-6		10
353	Neuro-Oncology. **2016**, 849-904		
352	Application of brush cytology for FISH-based detection of 1p/19q codeletion in oligodendroglial tumors. **2016**, 129, 415-422		7
351	Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). **2016**, 130, 31-42		29
350	A review of molecular alterations with clinical impact in adult and paediatric gliomas. **2016**, 22, 439-446		
349	Low-grade epilepsy-associated neuroepithelial tumours - the 2016 WHO classification. **2016**, 12, 732-740		58
348	5-hydroxymethylcytosine loss is associated with poor prognosis for patients with WHO grade II diffuse astrocytomas. **2016**, 6, 20882		21
347	Biobanking: An Important Resource for Precision Medicine in Glioblastoma. **2016**, 951, 47-56		2
346	Integrated multi-omics analysis of oligodendroglial tumours identifies three subgroups of 1p/19q co-deleted gliomas. **2016**, 7, 11263		55
345	Deletion and low expression of NFKBIA are associated with poor prognosis in lower-grade glioma patients. **2016**, 6, 24160		10
344	Establishment of Anti-Human ATRX Monoclonal Antibody AMab-6. **2016**, 35, 254-258		4
343	Compliance with reporting guidelines by Australian pathologists: an audit of the quality of histopathology reporting in high-grade glioma. **2016**, 3, 97-104		
342	Practical implications of integrated glioma classification according to the World Health Organization classification of tumors of the central nervous system 2016. **2016**, 28, 494-501		53
341	Therapiestrategien f□Glioblastome. **2016**, 19, 52-60		

340	Impact of IDH1 mutation status on outcome in clinical trials for recurrent glioblastoma. **2016**, 129, 147-54		25
339	Anaplastic astrocytoma. **2016**, 5, 145-57		31
338	Building diagnoses with four layers: WHO 2016 classification of CNS tumors. **2016**, 172, 253-5		6
337	TSPO expression in brain tumours: is TSPO a target for brain tumour imaging?. **2016**, 4, 145-156		43
336	Farewell to GBM-O: Genomic and transcriptomic profiling of glioblastoma with oligodendroglioma component reveals distinct molecular subgroups. **2016**, 4, 4		22
335	Prognostic value of the extent of resection in supratentorial WHO grade II astrocytomas stratified for IDH1 mutation status: a single-center volumetric analysis. **2016**, 129, 319-28		20
334	Mesenchymal/radioresistant traits in granular astrocytomas: evidence from a combined clinical and molecular approach. **2016**, 69, 329-37		2
333	Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology. **2016**, 131, 833-45		209
332	Common mutations in ALK2/ACVR1, a multi-faceted receptor, have roles in distinct pediatric musculoskeletal and neural orphan disorders. **2016**, 27, 93-104		41
331	Current Management of Adult Diffuse Infiltrative Low Grade Gliomas. **2016**, 16, 15		22
330	Prognostic significance of histomolecular subgroups of adult anaplastic (WHO Grade III) gliomas: applying the 'integrated' diagnosis approach. **2016**, 69, 686-94		17
329	Next-generation sequencing in routine brain tumor diagnostics enables an integrated diagnosis and identifies actionable targets. **2016**, 131, 903-10		151
328	TP53 Mutational Spectrum in Endometrioid and Serous Endometrial Cancers. **2016**, 35, 289-300		51
327	Gliomas Genomics and Epigenomics: Arriving at the Start and Knowing It for the First Time. **2016**, 11, 497-521		27
326	Primary Glial and Neuronal Tumors of the Ovary or Peritoneum: A Clinicopathologic Study of 11 Cases. **2016**, 40, 847-56		18
325	Genotyping low-grade gliomas among Hispanics. **2016**, 3, 164-172		2
324	Imaging of oligodendroglioma. **2016**, 89, 20150857		80
323	Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas. *Brain Tumor Pathology*, **2016**, 33, 107-16	3.2	33

322	Next-generation sequencing of central nervous systems tumors: the future of personalized patient management. **2016**, 18, 308-10		4
321	New Brain Tumor Entities Emerge from Molecular Classification of CNS-PNETs. **2016**, 164, 1060-1072		483
320	Central Nervous System: Progress of Today and a Preview of Tomorrow. **2016**, 94, 425-7		3
319	Surgical approaches for the gliomas. **2016**, 134, 51-69		18
318	Classification based on mutations of TERT promoter and IDH characterizes subtypes in grade II/III gliomas. **2016**, 18, 1099-108		71
317	Histologic classification of gliomas. **2016**, 134, 71-95		118
316	TERT Promoter Mutations and Risk of Recurrence in Meningioma. **2016**, 108,		189
315	The Challenge of Cancer Genomics in Rare Nervous System Neoplasms: Malignant Peripheral Nerve Sheath Tumors as a Paradigm for Cross-Species Comparative Oncogenomics. **2016**, 186, 464-77		29
314	The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas. **2016**, 75, 4-18		59
313	68Ga-NOTA-Aca-BBN(7-14) PET/CT in Healthy Volunteers and Glioma Patients. **2016**, 57, 9-14		47
312	BRAF alteration status and the histone H3F3A gene K27M mutation segregate spinal cord astrocytoma histology. **2016**, 131, 147-50		48
311	Histomolecular profiling of pleomorphic, spindle cell, and giant cell carcinoma of the lung for targeted therapies. **2016**, 49, 99-106		23
310	Combination of diffusion tensor imaging and conventional MRI correlates with isocitrate dehydrogenase 1/2 mutations but not 1p/19q genotyping in oligodendroglial tumours. **2016**, 26, 1705-15		46
309	Molecular classification of anaplastic oligodendroglioma using next-generation sequencing: a report of the prospective randomized EORTC Brain Tumor Group 26951 phase III trial. **2016**, 18, 388-400		102
308	Low Grade Gliomas in Children. **2016**, 31, 517-22		27
307	Mitosin and pHH3 predict poorer survival in astrocytomas WHO grades II and III. **2016**, 69, 26-34		12
306	ATRX in Diffuse Gliomas With its Mosaic/Heterogeneous Expression in a Subset. *Brain Pathology*, **2017**, 27, 138-145	6	11
305	ACTC1 as an invasion and prognosis marker in glioma. **2017**, 126, 467-475		21

304	Molecular Diagnostics of Gliomas Using Next Generation Sequencing of a Glioma-Tailored Gene Panel. *Brain Pathology*, **2017**, 27, 146-159	6	96
303	The new WHO 2016 classification of brain tumors-what neurosurgeons need to know. *Acta Neurochirurgica*, **2017**, 159, 403-418	3	59
302	Glioma: experimental models and reality. **2017**, 133, 263-282		165
301	Molecular Neuropathology and the Ontogeny of Malignant Gliomas. **2017**, 15-29		
300	Prognostic value of survivin and DNA topoisomerase II in diffuse and anaplastic astrocytomas. **2017**, 213, 339-347		1
299	Salvage therapy with bendamustine for temozolomide refractory recurrent anaplastic gliomas: a prospective phase II trial. **2017**, 131, 507-516		4
298	Immune checkpoint blockade for glioma. **2017**,		78
297	Diffuse low-grade glioma: a review on the new molecular classification, natural history and current management strategies. **2017**, 19, 931-944		64
296	DNA methylation signatures for 2016 WHO classification subtypes of diffuse gliomas. **2017**, 9, 32		18
295	Genomic Analysis in the Practice of Surgical Neuropathology: The Emory Experience. **2017**, 141, 355-365		2
294	The Role of Neurotrophin Signaling in Gliomagenesis: A Focus on the p75 Neurotrophin Receptor (p75/CD271). **2017**, 104, 367-404		9
293	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. **2017**, 5, 39		65
292	Molecular classification of adult diffuse gliomas: conflicting IDH1/IDH2, ATRX, and 1p/19q results. **2017**, 69, 15-22		20
291	Pathology of oligodendroglia: An overview. **2017**, 37, 465-474		8
290	Retrospective Analysis of Molecular and Immunohistochemical Characterization of 381 Primary Brain Tumors. **2017**, 76, 179-188		19
289	Diagnostic challenges in meningioma. **2017**, 19, 1588-1598		57
288	Alkaloids of fascaplysin are effective conventional chemotherapeutic drugs, inhibiting the proliferation of C6 glioma cells and causing their death. **2017**, 13, 738-746		12
287	Replication stress, DNA damage signalling, and cytomegalovirus infection in human medulloblastomas. **2017**, 11, 945-964		9

286	Overexpression of NIMA-related kinase 2 is associated with poor prognoses in malignant glioma. **2017**, 132, 409-417		17
285	A novel all-in-one intraoperative genotyping system for IDH1-mutant glioma. *Brain Tumor Pathology*, **2017**, 34, 91-97	3.2	11
284	Computational analysis of the mesenchymal signature landscape in gliomas. **2017**, 10, 13		2
283	Medulloblastoma in Adults. **2017**, 917-938		
282	Uncommon Pediatric Brain Tumors. **2017**, 1152-1171		
281	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. **2017**, 18, 682-694		336
280	Evaluation of non-supervised MALDI mass spectrometry imaging combined with microproteomics for glioma grade III classification. **2017**, 1865, 875-890		27
279	Advances in the molecular genetics of gliomas - implications for classification and therapy. **2017**, 14, 434-452		320
278	Targeted Next-Generation Sequencing in Molecular Subtyping of Lower-Grade Diffuse Gliomas: Application of the World Health Organization's 2016 Revised Criteria for Central Nervous System Tumors. **2017**, 19, 328-337		22
277	Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy. **2017**, 133, 1-3		77
276	Pyrrolidine dithiocarbamate sensitizes U251 brain glioma cells to temozolomide via downregulation of and. **2017**, 14, 5135-5144		2
275	2016 Updates to the WHO Brain Tumor Classification System: What the Radiologist Needs to Know. **2017**, 37, 2164-2180		72
274	Updated 2016 WHO classification of tumors of the CNS: turning the corner where molecule meets pathology. *Brain Tumor Pathology*, **2017**, 34, 139-140	3.2	10
273	Diagnostic implications of TERT promoter mutation status in diffuse gliomas in a routine clinical setting. **2017**, 471, 641-649		6
272	The 2016 WHO classification of central nervous system tumors: what neurologists need to know. **2017**, 30, 643-649		42
271	Molecular Pathology of Glioblastoma- An Update. **2017**, 19-55		
270	Imaging correlates for the 2016 update on WHO classification of grade II/III gliomas: implications for IDH, 1p/19q and ATRX status. **2017**, 135, 601-609		54
269	Imaging Correlates of Adult Glioma Genotypes. **2017**, 284, 316-331		93

268	Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome. **2017**, 134, 705-714		114
267	Grading of diffuse astrocytic gliomas: Broders, Kernohan, Zülch, the WHO and Shakespeare. **2017**, 134, 517-520		9
266	The Updated World Health Organization Glioma Classification: Cellular and Molecular Origins of Adult Infiltrating Gliomas. **2017**, 141, 1633-1645		24
265	IDH1 status is significantly different between high-grade thalamic and superficial gliomas. **2017**, 20, 183-189		2
264	Cost-effectiveness of IDH testing in diffuse gliomas according to the 2016 WHO classification of tumors of the central nervous system recommendations. **2017**, 19, 1640-1650		36
263	cIMPACT-NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification. *Brain Pathology*, **2017**, 27, 851-852	6	36
262	Diagnostic revision of 206 adult gliomas (including 40 oligoastrocytomas) based on ATRX, IDH1/2 and 1p/19q status. **2017**, 131, 213-222		17
261	Interference with the HSF1/HSP70/BAG3 Pathway Primes Glioma Cells to Matrix Detachment and BH3 Mimetic-Induced Apoptosis. **2017**, 16, 156-168		48
260	Genetic alterations related to BRAF-FGFR genes and dysregulated MAPK/ERK/mTOR signaling in adult pilocytic astrocytoma. *Brain Pathology*, **2017**, 27, 580-589	6	19
259	In vivo molecular profiling of human glioma using diffusion kurtosis imaging. **2017**, 131, 93-101		41
258	Low-Grade Gliomas. *Pediatric Oncology*, **2017**, 1-35	0.5	
257	Targeting cancer stem-like cells in glioblastoma and colorectal cancer through metabolic pathways. **2017**, 140, 10-22		43
256	Pathology and Molecular Pathology of Brain Cancer. **2017**, 291-311		1
255	The 2016 WHO Classification of Tumours of the Central Nervous System: The Major Points of Revision. **2017**, 57, 301-311		134
254	Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. **2017**, 8, 15071-15084		10
253	Epigenetic dysregulation in brain tumors and neurodevelopment. **2017**, 261-276		
252	Improved Pathologic Diagnosis-Forecasting the Future in Glioblastoma. **2017**, 8, 707		3
251	Expression Levels and Localizations of DVL3 and sFRP3 in Glioblastoma. **2017**, 2017, 9253495		9

250	Postoperative extracranial metastasis from glioblastoma: a case report and review of the literature. **2017**, 15, 231	15
249	Treatment Recommendations for Adult Patients with Diffuse Gliomas of Grades II and III According to the New WHO Classification in 2016. **2017**, 57, 658-666	7
248	Brain tumor epidemiology in the era of precision medicine: The 2017 Brain Tumor Epidemiology Consortium meeting report. **2017**, 36, 255-263	7
247	Molecular Testing of Brain Tumor. **2017**, 51, 205-223	44
246	New Classification for Central Nervous System Tumors: Implications for Diagnosis and Therapy. **2017**, 37, 753-763	2
245	Conditional survival after a diagnosis of malignant brain tumour in Canada: 2000-2008. **2017**, 24, e341-e347	3
244	Metastatic group 3 medulloblastoma is driven by PRUNE1 targeting NME1-TGF-□OTX2-SNAIL via PTEN inhibition. **2018**, 141, 1300-1319	13
243	Incorporating Advances in Molecular Pathology Into Brain Tumor Diagnostics. **2018**, 25, 143-171	23
242	Integrated neurodegenerative disease autopsy diagnosis. **2018**, 135, 643-646	7
241	Grading of oligodendroglial tumors of the brain with apparent diffusion coefficient, magnetic resonance spectroscopy, and dynamic susceptibility contrast imaging. **2018**, 31, 379-385	5
240	Texture analysis- and support vector machine-assisted diffusional kurtosis imaging may allow in vivo gliomas grading and IDH-mutation status prediction: a preliminary study. **2018**, 8, 6108	34
239	Novel, improved grading system(s) for IDH-mutant astrocytic gliomas. **2018**, 136, 153-166	162
238	Sequencing the next generation of glioblastomas. **2018**, 55, 264-282	14
237	Reconstructing the molecular life history of gliomas. **2018**, 135, 649-670	44
236	Adoptive Immunotherapy Using PRAME-Specific T Cells in Medulloblastoma. **2018**, 78, 3337-3349	41
235	lncRNA-based study of epigenetic regulations in diabetic peripheral neuropathy. **2018**, 6, 7	8
234	Single-Cell RNA-Sequencing in Glioma. **2018**, 20, 42	11
233	Circulating Micrornas Predict Survival of Patients with Tumors of Glial Origin. **2018**, 30, 105-112	13

232	Glioma through the looking GLASS: molecular evolution of diffuse gliomas and the Glioma Longitudinal Analysis Consortium. **2018**, 20, 873-884	63
231	cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC). **2018**, 135, 481-484	78
230	p53 expression and subcellular survivin localization improve the diagnosis and prognosis of patients with diffuse astrocytic tumors. **2018**, 41, 141-157	9
229	Recurrence patterns after maximal surgical resection and postoperative radiotherapy in anaplastic gliomas according to the new 2016 WHO classification. **2018**, 8, 777	17
228	STAT3 Gene Silencing by Aptamer-siRNA Chimera as Selective Therapeutic for Glioblastoma. **2018**, 10, 398-411	53
227	Optical Analysis of Glioma: Fourier-Transform Infrared Spectroscopy Reveals the Mutation Status. **2018**, 24, 2530-2538	16
226	Molecular Basis of Diseases of the Nervous System. **2018**, 651-690	1
225	Analysis of immunobiologic markers in primary and recurrent glioblastoma. **2018**, 137, 249-257	23
224	Glioma imaging in Europe: A survey of 220 centres and recommendations for best clinical practice. **2018**, 28, 3306-3317	88
223	Apparent diffusion coefficient for molecular subtyping of non-gadolinium-enhancing WHO grade II/III glioma: volumetric segmentation versus two-dimensional region of interest analysis. **2018**, 28, 3779-3788	41
222	Spheno-Orbital Meningiomas: An Analysis Based on World Health Organization Classification and Ki-67 Proliferative Index. **2018**, 34, 143-150	8
221	Oligodendroglioma resection: a Surveillance, Epidemiology, and End Results (SEER) analysis. **2018**, 128, 1076-1083	26
220	Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. **2018**, 128, 1102-1114	16
219	Identification of New Biomarkers Associated With IDH Mutation and Prognosis in Astrocytic Tumors Using NanoString nCounter Analysis System. **2018**, 26, 101-107	7
218	Brainstem pilocytic astrocytoma with H3 K27M mutation: case report. **2018**, 129, 593-597	17
217	The case for DNA methylation based molecular profiling to improve diagnostic accuracy for central nervous system embryonal tumors (not otherwise specified) in adults. **2018**, 47, 163-167	5
216	Imaging Genetic Heterogeneity in Glioblastoma and Other Glial Tumors: Review of Current Methods and Future Directions. **2018**, 210, 30-38	35
215	CNS embryonal tumours: WHO 2016 and beyond. **2018**, 44, 151-162	24

214	In vivo assessment of tumor heterogeneity in WHO 2016 glioma grades using diffusion kurtosis imaging: Diagnostic performance and improvement of feasibility in routine clinical practice. **2018**, 45, 32-40	25
213	Neurological update: gliomas and other primary brain tumours in adults. **2018**, 265, 717-727	18
212	Integrating Molecular Diagnostics With Surgical Neuropathology. **2018**, 71-89	1
211	Astrocytic and Oligodendroglial Tumors. **2018**, 91-123	0
210	Embryonal Neoplasms of the Central Nervous System. **2018**, 233-258	1
209	Prediction of -Mutation and 1p/19q-Codeletion Status Using Preoperative MR Imaging Phenotypes in Lower Grade Gliomas. **2018**, 39, 37-42	69
208	WHO 2016 Classification of gliomas. **2018**, 44, 139-150	331
207	A simple algorithmic approach using histology and immunohistochemistry for the current classification of adult diffuse glioma in a resource-limited set-up. **2018**, 71, 323-329	8
206	Year 1 in the Molecular Era of Pediatric Brain Tumor Diagnosis: Application of Universal Clinical Targeted Sequencing in an Unselected Cohort of Children.. **2018**, 2, 1-13	0
205	Reclassification of Mixed Oligoastrocytic Tumors Using a Genetically Integrated Diagnostic Approach. **2018**, 52, 28-36	2
204	Glioblastoma: Pathology and Genetics. **2018**,	
203	Introduction to the Special Issue on Pediatric Neuro-Oncology. **2018**, 5,	
202	The 2016 World Health Organization classification of tumours of the central nervous system. **2018**, 47, e187-e200	37
201	Expression of activating transcription factor 5 (ATF5) is increased in astrocytomas of different WHO grades and correlates with survival of glioblastoma patients. **2018**, 11, 8673-8684	13
200	Modern Principles of CNS Tumor Classification. **2018**, 117-129	
199	cIMPACT-NOW update 3: recommended diagnostic criteria for "Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV". **2018**, 136, 805-810	367
198	Medulloblastoma. **2018**,	
197	Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. **2018**, 30, 556-562	5

196	The Multifaceted Metabolism of Glioblastoma. **2018**, 1063, 59-72		14
195	Elevated TERT Expression in TERT-Wildtype Adult Diffuse Gliomas: Histological Evaluation with a Novel TERT-Specific Antibody. **2018**, 2018, 7945845		12
194	World Health Organization 2016 Classification of Central Nervous System Tumors. **2018**, 36, 439-447		47
193	Evolving Insights into the Molecular Neuropathology of Diffuse Gliomas in Adults. **2018**, 36, 421-437		7
192	Epitope mapping of an anti-alpha thalassemia/mental retardation syndrome X-linked monoclonal antibody AMab-6. **2018**, 15, 76-80		0
191	Licochalcone A attenuates glioma cell growth in vitro and in vivo through cell cycle arrest. **2018**, 9, 4500-4507		22
190	Is there an increased risk of spinal relapse in standard-risk medulloblastoma/primitive neuroectodermal tumor patients who receive only a reduced dose of craniospinal radiotherapy?. **2018**, 34, 1657-1662		
189	Personalized regulation of glioblastoma cancer stem cells based on biomedical technologies: From theory to experiment (Review). **2018**, 42, 691-702		5
188	Quantitative magnetic resonance imaging and radiogenomic biomarkers for glioma characterisation: a systematic review. **2018**, 91, 20170930		21
187	Diffuse Astrocytoma and Oligodendroglioma: An Integrated Diagnosis and Management. **2019**,		
186	Extra-axial Tumors. **2019**, 1115-1150		1
185	Differences in spatial distribution between WHO 2016 low-grade glioma molecular subgroups. *Neuro-Oncology Advances*, **2019**, 1, vdz001	0.9	4
184	Prognostic Roles of Central Carbon Metabolism-Associated Genes in Patients With Low-Grade Glioma. **2019**, 10, 831		1
183	Multiparametric and multiregional diffusion features help predict molecule information, grade and survival in lower-grade gliomas: a feasibility study. **2019**, 92, 20190324		1
182	Cancer collection efforts in the United States provide clinically relevant data on all primary brain and other CNS tumors. **2019**, 6, 330-339		10
181	Pathogenic Epigenetic Consequences of Genetic Alterations in IDH-Wild-Type Diffuse Astrocytic Gliomas. **2019**, 79, 4814-4827		2
180	Pathology and Classification of Tumors of the Central Nervous System. **2019**, 3-89		
179	Molecular pathology of tumors of the central nervous system. **2019**, 30, 1265-1278		63

178	Thalamic Gliomas. **2019**, 459-480		1
177	Systematic expression analysis of ligand-receptor pairs reveals important cell-to-cell interactions inside glioma. **2019**, 17, 48		17
176	Extensive Pachymeningeal Dissemination of Glioblastoma Mimicking Chronic Subdural Hematoma: A Case Report. *Brain Tumor Research and Treatment*, **2019**, 7, 39-43	1.4	3
175	The ABCs of molecular diagnostic testing of CNS tumors: acceptance, benefits, costs. **2019**, 21, 559-561		0
174	Approach to molecular subgrouping of medulloblastomas: Comparison of NanoString nCounter assay versus combination of immunohistochemistry and fluorescence□in-situ hybridization in resource constrained centres. **2019**, 143, 393-403		6
173	, , and Status Predicts Prognosis in Glioma. *Cancers*, **2019**, 11,	6.6	12
172	Quantitative Third Harmonic Generation Microscopy for Assessment of Glioma in Human Brain Tissue. **2019**, 6, 1900163		6
171	Extra-axial Tumors. **2019**, 1-37		
170	What Every Neuropathologist Needs to Know: Update on cIMPACT-NOW. **2019**, 78, 294-296		8
169	cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAF mutation. **2019**, 137, 683-687		92
168	Glioblastoma diagnostics and prognostic biomarkers: Current status in medicine and exosome derivation. **2019**, 9, 65-73		1
167	Applications of molecular neuro-oncology - a review of diffuse glioma integrated diagnosis and emerging molecular entities. **2019**, 14, 29		24
166	Recent developments and future directions in adult lower-grade gliomas: Society for Neuro-Oncology (SNO) and European Association of Neuro-Oncology (EANO) consensus. **2019**, 21, 837-853		37
165	Feature enhancement framework for brain tumor segmentation and classification. **2019**, 82, 803-811		38
164	The therapeutic and diagnostic potential of regulatory noncoding RNAs in medulloblastoma. *Neuro-Oncology Advances*, **2019**, 1, vdz023	0.9	13
163	Longitudinal molecular trajectories of diffuse glioma in adults. **2019**, 576, 112-120		151
162	PRDM10-rearranged Soft Tissue Tumor: A Clinicopathologic Study of 9 Cases. **2019**, 43, 504-513		17
161	The central nervous system tumor methylation classifier changes neuro-oncology practice for challenging brain tumor diagnoses and directly impacts patient care. **2019**, 11, 185		25

160	A little piece of mind: best practices for brain tumor intraoperative consultation. **2019**, 32, 44-57		3
159	Conventional MR-based Preoperative Nomograms for Prediction of IDH/1p19q Subtype in Low-Grade Glioma. **2019**, 26, 1062-1070		11
158	IDH mutant astrocytoma: biomarkers for prognostic stratification and the next frontiers. **2019**, 45, 91-94		2
157	Genotype-phenotype correlations in focal malformations of cortical development: a pathway to integrated pathological diagnosis in epilepsy surgery. *Brain Pathology*, **2019**, 29, 473-484	6	7
156	A CK1Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma. **2019**, 25, 1379-1388		14
155	Data Sets for the Reporting of Tumors of the Central Nervous System: Recommendations From The International Collaboration on Cancer Reporting. **2020**, 144, 196-206		9
154	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. **2020**, 139, 193-209		35
153	Primary sellar melanocytoma: pathological, clinical and treatment review. **2020**, 43, 575-585		1
152	Detection of BRAF V600E mutation by immunohistochemistry and PCR-RFLP in Moroccan patients with Pediatric Low-Grade Gliomas. **2020**, 18, 100572		
151	Clinical Significance of Somatostatin Receptor (SSTR) 2 in Meningioma. *Frontiers in Oncology*, **2020**, 10, 1633	5.3	6
150	A machine learning analysis of a "normal-like" IDH-WT diffuse glioma transcriptomic subgroup associated with prolonged survival reveals novel immune and neurotransmitter-related actionable targets. **2020**, 18, 280		2
149	Medulloblastoma: "Onset of the molecular era". **2020**, 47, 9931-9937		4
148	Updates in Pediatric Glioma Pathology. **2020**, 13, 801-816		4
147	Alkaloids of fascaplysin are promising chemotherapeutic agents for the treatment of glioblastoma: Review. **2020**, 151, 299-324		3
146	Molecular and Clinical Characterization of a Novel Prognostic and Immunologic Biomarker FAM111A in Diffuse Lower-Grade Glioma. *Frontiers in Oncology*, **2020**, 10, 573800	5.3	3
145	Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy. **2020**, 7, 562798		20
144	Updates in Pediatric Malignant Gliomas. **2020**, 29, 83-94		2
143	Molecular markers and targeted therapy in pediatric low-grade glioma. **2020**, 150, 5-15		10

142	Adult Glioma WHO Classification Update, Genomics, and Imaging: What the Radiologists Need to Know. **2020**, 29, 71-82		19
141	Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System. **2020**, 25, 997-1003		11
140	Lower Grade Gliomas. **2020**, 20, 21		22
139	cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors. *Brain Pathology*, **2020**, 30, 863-866	6	51
138	Pediatric low-grade glioma in the era of molecular diagnostics. **2020**, 8, 30		52
137	Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status. **2020**, 20, 149		13
136	Central nervous system neuroepithelial tumors with MN1-alteration: an individual patient data meta-analysis of 73 cases. *Brain Tumor Pathology*, **2020**, 37, 145-153	3.2	7
135	Loss of 5'-Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness. **2020**, 9,		5
134	TERT Promoter Mutation Analysis to Distinguish Glioma From Gliosis. **2020**, 79, 430-436		1
133	Brain tumour diagnostics using a DNA methylation-based classifier as a diagnostic support tool. **2020**, 46, 478-492		18
132	Clinical implications of intratumor heterogeneity: challenges and opportunities. **2020**, 98, 161-177		95
131	cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas. **2020**, 139, 603-608		170
130	T2 mapping of molecular subtypes of WHO grade II/III gliomas. **2020**, 20, 8		8
129	Pathology, diagnostics, and classification of medulloblastoma. *Brain Pathology*, **2020**, 30, 664-678	6	17
128	Glioblastoma: Pathogenesis and Current Status of Chemotherapy and Other Novel Treatments. *Cancers*, **2020**, 12,	6.6	30
127	World Health Organization Grade II/III Glioma Molecular Status: Prediction by MRI Morphologic Features and Apparent Diffusion Coefficient. **2020**, 296, 111-121		20
126	cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading. *Brain Pathology*, **2020**, 30, 844-856	6	196
125	Extent of resection in diffuse low-grade gliomas and the role of tumor molecular signature-a systematic review of the literature. **2021**, 44, 1371-1389		5

124	Linking epigenetic signature and metabolic phenotype in IDH mutant and IDH wildtype diffuse glioma. **2021**, 47, 379-393		1
123	Prognostic relevance of adding MRI data to WHO 2016 and cIMPACT-NOW updates for diffuse astrocytic tumors in adults. Working toward the extended use of MRI data in integrated glioma diagnosis. *Brain Pathology*, **2021**, 31, e12929	6	1
122	Low-grade gangliogliomas in adults: A population-based study. **2021**, 10, 416-423		3
121	Subgroup stratification of adult diffuse gliomas and outcomes: an adaptation of the updated WHO classification in a resource-constrained environment. **2021**, 20, 55-58		
120	Glioma Diagnosis and Classification: Illuminating the Gold Standard. **2021**, 3-10		
119	Tumors of the Central Nervous System. **2021**, 121-145		
118	Guanabenz Sensitizes Glioblastoma Cells to Sunitinib by Inhibiting GADD34-Mediated Autophagic Signaling. **2021**, 18, 1371-1392		2
117	GATOR1-related focal cortical dysplasia in epilepsy surgery patients and their families: A possible gradient in severity?. **2021**, 30, 88-96		2
116	Mass-spectrometry-based proteomic correlates of grade and stage reveal pathways and kinases associated with aggressive human cancers. **2021**, 40, 2081-2095		8
115	Pediatric Glioma: An Update of Diagnosis, Biology, and Treatment. *Cancers*, **2021**, 13,	6.6	7
114	A CORRELATION OF CLINICOPATHOLOGICAL AND RADIOLOGICAL FINDINGS OF CENTRAL NERVES SYSTEM TUMOURS. **2021**, 17-20		
113	Current applications of deep-learning in neuro-oncological MRI. **2021**, 83, 161-173		5
112	A Systematic Review of Glioblastoma-Targeted Therapies in Phases II, III, IV Clinical Trials. *Cancers*, **2021**, 13,	6.6	17
111	Molecular biomarkers and integrated pathological diagnosis in the reclassification of gliomas. **2021**, 15, 150		0
110	Classification of Diffuse Glioma Subtype from Clinical-Grade Pathological Images Using Deep Transfer Learning. **2021**, 21,		1
109	Imaging Findings of New Entities and Patterns in Brain Tumor: Isocitrate Dehydrogenase Mutant, Isocitrate Dehydrogenase Wild-Type, Codeletion, and MGMT Methylation. **2021**, 59, 305-322		1
108	Differential expression of stem cell markers in proliferating cells in glioma. **2021**, 147, 2969-2982		1
107	Extracellular Sphingosine-1-Phosphate Downstream of EGFR Increases Human Glioblastoma Cell Survival. *International Journal of Molecular Sciences*, **2021**, 22,	6.3	1

106	The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. **2021**, 23, 1231-1251	708
105	Association of IDH mutation and 1p19q co-deletion with tumor immune microenvironment in lower-grade glioma. **2021**, 21, 288-302	7
104	Simplified approach for pathological diagnosis of diffuse gliomas in adult patients. **2021**, 223, 153483	0
103	Role of neutrophil-lymphocyte ratio as a predictive factor of glioma tumor grade: A systematic review. **2021**, 163, 103372	6
102	Comparative evaluation of squash smear and frozen section in the intraoperative diagnosis of central nervous system tumours. **2021**,	0
101	Decreased Expression of PACSIN1 in Brain Glioma Samples Predicts Poor Prognosis. **2021**, 8, 696072	1
100	Congenital and Perinatal Brain Tumors. **2021**, 285-300	
99	Propranolol Inhibits the Proliferation of Human Glioblastoma Cell Lines through Notch1 and Hes1 Signaling System. **2021**, 64, 716-725	2
98	Natural bioactive molecules: An alternative approach to the treatment and control of glioblastoma multiforme. **2021**, 141, 111928	14
97	Grading of adult diffuse gliomas according to the 2021 WHO Classification of Tumors of the Central Nervous System. **2021**,	10
96	Pathology and Molecular Biology of Medulloblastoma. **2021**, 79-88	
95	Pathology, Molecular Biology and Classification of Gliomas. **2021**, 37-55	
94	Characterization of primary glioma cell lines derived from the patients according to 2016 CNS tumour WHO classification and comparison with their parental tumours. **2021**, 151, 123-133	1
93	Molecular-Genetic Classification of Gliomas and Its Practical Application to Diagnostic Neuropathology. **2017**, 73-100	1
92	Genomic Biomarker Assessment in Gliomas: Impacts of Molecular Testing on Clinical Practice and Trial Design. **2020**, 13, 209-215	2
91	Reconstructing the Molecular Life History of Gliomas.	2
90	2016 World Health Organization Classification of Central Nervous System Tumors. **2017**, 23, 1531-1547	62
89	EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. **2015**, 40, 739-749	22

88	Automated Analysis of 1p/19q Status by FISH in Oligodendroglial Tumors: Rationale and Proposal of an Algorithm. **2015**, 10, e0132125		5
87	The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade II Cerebral Gliomas in Adults: Version 2019.01. *Brain Tumor Research and Treatment*, **2019**, 7, 74-84	1.4	4
86	DNA repair genes in astrocytoma tumorigenesis, progression and therapy resistance. **2019**, 43, e20190066		9
85	PROX1 is a novel pathway-specific prognostic biomarker for high-grade astrocytomas; results from independent glioblastoma cohorts stratified by age and IDH mutation status. **2016**, 7, 72431-72442		8
84	Combination of AQP1 and Ecatenin expression is an independent prognosis factor in astrocytoma patients. **2017**, 8, 99414-99428		1
83	IDH mutation, 1p19q codeletion and ATRX loss in WHO grade II gliomas. **2015**, 6, 30295-305		86
82	Co-expression of mitosis-regulating genes contributes to malignant progression and prognosis in oligodendrogliomas. **2015**, 6, 38257-69		10
81	Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas. **2016**, 7, 21190-8		15
80	Omics-based integrated analysis identified ATRX as a biomarker associated with glioma diagnosis and prognosis. **2019**, 16, 784-796		13
79	Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution. **2017**,		1
78	Correlation of Molecular Markers in High Grade Gliomas with Response to Chemo-Radiation. **2020**, 21, 755-760		2
77	Is IDH status the only factor predicting prognosis in newly diagnosed anaplastic glioma patients? Outcome evaluation and prognostic factor analysis in a single-institution large series. **2020**, 1-14		5
76	Alpha Internexin: A Surrogate Marker for 1p/19q Codeletion and Prognostic Marker in Anaplastic (WHO grade III) Gliomas. **2020**, 68, 832-837		3
75	, , and V600E mutation in astrocytic tumors and their significance in patient outcome in north Indian population. **2018**, 9, 29		6
74	Assessment of accessibility to the diagnosis and treatment of brain tumors in Argentina: Preliminary results. **2017**, 8, 118		4
73	Identification of gene expression and DNA methylation of and as novel prognostic markers in lower-grade gliomas. **2020**, 8, e9262		2
72	Standardized Molecular and Genetic Diagnosis of Medulloblastoma. *Japanese Journal of Neurosurgery*, **2015**, 24, 436-444	0	1
71	Refined Glioma Classification based on Molecular Pathology. *Japanese Journal of Neurosurgery*, **2015**, 24, 366-377	0	

70	Atypical Teratoid-Rhabdoid Tumor. **2016**, 544-547		
69	Therapeutic Strategies for Medulloblastoma based on its Molecular and Genetic Diagnosis. *Japanese Journal of Neurosurgery*, **2016**, 25, 307-314	0	
68	An Overview of the History of Brain Tumor Classification and Glioma Diagnosis in WHO2016. *Japanese Journal of Neurosurgery*, **2016**, 25, 542-547	0	
67	Gliomas. **2016**, 507-514		
66	Brain and Spinal Cord. **2017**, 865-877		
65	3.0T Imaging of Brain Gliomas. **2017**, 271-319		
64	Glioma Through the Looking GLASS: the Glioma Longitudinal Analysis consortium, molecular evolution of diffuse gliomas.		
63	Pediatric Glioma. *Pediatric Oncology*, **2018**, 171-202	0.5	
62	Atypical Teratoid/Rhabdoid Tumor (AT/RT). *Pediatric Oncology*, **2018**, 221-242	0.5	0
61	Molecular Diagnosis in WHO Classification of Tumours of the Central Nervous System 2016 : A Domestic Survey and Perspectives. *Japanese Journal of Neurosurgery*, **2019**, 28, 674-685	0	
60	The Korean Society for Neuro-Oncology (KSNO) Guideline for WHO Grade III Cerebral Gliomas in Adults: Version 2019.01. *Brain Tumor Research and Treatment*, **2019**, 7, 63-73	1.4	3
59	Machine learning assisted DSC-MRI radiomics as a tool for glioma classification by grade and mutation status.		
58	Review of WHO 2016 Changes to Classification of Gliomas; Incorporation of Molecular Markers. **2020**, 127-138		1
57	The Role of Next Generation Sequencing in Diagnosis of Brain Tumors: A Review Study. *Archives of Neuroscience*, **2019**, 7,	1.2	0
56	Modern Treatments for Gliomas Improve Outcome. *Current Cancer Therapy Reviews*, **2020**, 16, 221-245	0.4	
55	Personalized Management of Cancers of Various Organs/Systems. **2021**, 509-602		
54	Canine Gliomatosis Cerebri: Morphologic and Immunohistochemical Characterization Is Supportive of Glial Histogenesis. *Veterinary Pathology*, **2021**, 58, 293-304	2.8	1
53	Pathology, Epidemiology, and WHO Classification of Brain Tumors. **2020**, 3-13		1

52	[Glioblastomas in patients with medulloblastomas after combined treatment]. *Zhurnal Voprosy Nejrokhirurgii Imeni N N Burdenko*, **2020**, 84, 35-41		
51	Glioblastoma. **2020**, 173-182		
50	Myxopapillary Ependymoma of the III Ventricle: Example of a Histological Variant of Ependymoma with Exceptional Localization. *Open Journal of Pathology*, **2020**, 10, 51-55	0.1	
49	Biomarkers for glioblastoma multiforme: status quo. *Journal of Clinical and Translational Research*, **2016**, 2, 3-10	1.1	7
48	Integrating m6A Regulators-Mediated Methylation Modification Models and Tumor Immune Microenvironment Characterization in Caucasian and Chinese Low-Grade Gliomas.. *Frontiers in Cell and Developmental Biology*, **2021**, 9, 725764	5.7	1
47	Development and Validation of an Immune-Related Gene Pairs Signature in Grade II/III Glioma. *International Journal of General Medicine*, **2021**, 14, 8611-8620	2.3	
46	Applications of Radiomics and Radiogenomics in High-Grade Gliomas in the Era of Precision Medicine. *Cancers*, **2021**, 13,	6.6	3
45	Primary Brain Neoplasms. **2022**, 539-563		
44	Transcriptional Networks Identify BRPF1 as a Potential Drug Target Based on Inflammatory Signature in Primary Lower-Grade Gliomas.. *Frontiers in Oncology*, **2021**, 11, 766656	5.3	0
43	Application of terahertz technologies in glioma diagnosis: from histological classification to molecular typing. *Wuli Xuebao/Acta Physica Sinica*, **2022**,	0.6	
42	Diagnostic performance of DSC perfusion MRI to distinguish tumor progression and treatment-related changes: a systematic review and meta-analysis.. *Neuro-Oncology Advances*, **2022**, 4, vdac027	0.9	
41	Therapeutic Approaches in Adult Primary Spinal Cord Astrocytoma: A Systematic Review.. *Cancers*, **2022**, 14,	6.6	
40	The 2021 WHO classification of tumors, 5th edition, central nervous system tumors: the 10 basic principles.. *Brain Tumor Pathology*, **2022**, 1	3.2	3
39	Piecing Together a Puzzle of Exceptional Lesions: A Retrospective Study of a Potpourri of 160 Space-Occupying Lesions of the Central Nervous System.. *Cureus*, **2022**, 14, e23585	1.2	
38	Protective Prognostic Biomarkers Negatively Correlated with Macrophage M2 Infiltration in Low-Grade Glioma.. *Journal of Oncology*, **2022**, 2022, 3623591	4.5	
37	Relapsed Medulloblastoma in Pre-Irradiated Patients: Current Practice for Diagnostics and Treatment.. *Cancers*, **2021**, 14,	6.6	1
36	Gene Alterations Define Specific Features of a Subset of Glioblastomas.. *International Journal of Molecular Sciences*, **2021**, 23,	6.3	1
35	Galectins as Emerging Glyco-Checkpoints and Therapeutic Targets in Glioblastoma.. *International Journal of Molecular Sciences*, **2021**, 23,	6.3	2

34	A Summary of the Inaugural WHO Classification of Pediatric Tumors: Transitioning from the Optical into the Molecular Era.. *Cancer Discovery*, **2021**,	24.4	5
33	Potential of IDH mutations as immunotherapeutic targets in gliomas: a review and meta-analysis.. *Expert Opinion on Therapeutic Targets*, **2021**,	6.4	2
32	Table_1.docx. **2019**,		
31	DataSheet_1.pdf. **2020**,		
30	Table_1.xlsx. **2020**,		
29	Effects of Long-Term Temozolomide Treatment on Glioblastoma and Astrocytoma WHO Grade 4 Stem-like Cells.. *International Journal of Molecular Sciences*, **2022**, 23,	6.3	
28	Preoperative and Noninvasive Prediction of Gliomas Histopathological Grades and IDH Molecular Types Using Multiple MRI Characteristics. *Frontiers in Oncology*, 12,	5.3	1
27	Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma. *Biomaterials*, **2022**, 121608	15.6	2
26	Pediatric high-grade gliomas and the WHO CNS Tumor Classification: Perspectives of pediatric neuro-oncologists and neuropathologists in light of recent updates. *Neuro-Oncology Advances*, **2022**, 4,	0.9	0
25	Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications. *Frontiers in Oncology*, 12,	5.3	
24	A simplified overview of the World Health Organization classification of central nervous system tumors 2021. 13, 252		1
23	3D Bioprinted Glioma Models. *Progress in Biomedical Engineering*,	7.2	2
22	Laboratory testing in pediatric cancer patients. **2022**, 31-65		
21	A Novel Thrombosis-Related Signature for Predicting Survival and Drug Compounds in Glioblastoma. *Journal of Oncology*, **2022**, 2022, 1-16	4.5	
20	The WHO 2021 Classification of Central Nervous System tumours: a practical update on what neurosurgeons need to know minireview. *Acta Neurochirurgica*,	3	3
19	2021 WHO classification of tumours of the central nervous system: a review for the neuroradiologist. *Neuroradiology*,	3.2	1
18	Inter-pathologist Agreement on Diagnosis, Classification and Grading of Canine Glioma. *Veterinary and Comparative Oncology*,	2.5	
17	Paediatric brain tumours. **2022**, 739-765		0

16	ATRX status in patients with gliomas: Radiomics analysis. **2022**, 101, e30189	1
15	Major features of the 2021 WHO Classification of Tumors of the Central Nervous System: clinician view. **2022**, 2, 77-90	0
14	PROTEIN ARGININE METHYLTRANSFERASE 5 regulates SHH-subgroup medulloblastoma progression.	0
13	Pituitary carcinoma - case series and review of the literature. 13,	1
12	Updated classification of tumors of the central nervous system as the basis for individual patient therapy. **2022**, 2, 6-13	1
11	COMMD4 is a novel prognostic biomarker and relates to potential drug resistance mechanism in glioma. 13,	0
10	The 2021 WHO classification of central nervous system tumors: what neurologists need to know. Publish Ahead of Print,	2
9	The path towards consensus genome classification of diffuse large B-cell lymphoma for use in clinical practice. 12,	0
8	Rare embryonal and sarcomatous central nervous system tumours: State-of-the art and future directions. **2023**, 66, 104660	0
7	Genomic profiles of IDH-mutant gliomas: MYCN amplified IDH-mutant astrocytoma had the worst prognosis.	0
6	Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5. Volume 16, 107-127	0
5	Emerging Perspectives on the Antiparasitic Mebendazole as a Repurposed Drug for the Treatment of Brain Cancers. **2023**, 24, 1334	0
4	Low-grade epilepsy-associated neuroepithelial tumors: Tumor spectrum and diagnosis based on genetic alterations. 16,	0
3	Genomic profiles of IDH-mutant gliomas: MYCN amplified IDH-mutant astrocytoma had the worst prognosis and true mixed oligoastrocytoma does not exist.	0
2	Pediatric brain tumors: A neuropathologist's approach to the integrated diagnosis. 11,	0
1	Refining the Intraoperative Identification of Suspected High-Grade Glioma Using a Surgical Fluorescence Biomarker: GALA BIDD Study Report. **2023**, 13, 514	0